Targeting hyperactivation of the <scp>AKT</scp> survival pathway to overcome therapy resistance of melanoma brain metastases
Heike Niessner(University of Tübingen), Friedegund Meier(National Center for Tumor Diseases)
Cited by 152
Related Papers
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts
|European Journal of Cancer|2021|246
Human Melanoma Progression in Skin Reconstructs
|American Journal Of Pathology|2000|236
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|72
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma
|European Journal of Cancer|2019|26